Antibodies

21 Apr 2009 Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
21 Apr 2009 Lpath Scientists and Collaborators Present Favorable New Study Data of Leading Cancer Drug Candidate, ASONEP(TM)
21 Apr 2009 Seattle Genetics Highlights Dacetuzumab Preclinical Research at AACR
20 Apr 2009 AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)
20 Apr 2009 Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research
20 Apr 2009 Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
20 Apr 2009 Immunomedics Expands Product Pipeline for Potential Therapy of Cancer and Inflammatory Diseases
20 Apr 2009 AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
10 Apr 2009 ArmaGen plans First in Human clinical trial
08 Apr 2009 Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
08 Apr 2009 BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
08 Apr 2009 Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
06 Apr 2009 Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Millennium
06 Apr 2009 Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
03 Apr 2009 Arzerra (TM) (ofatumumab) granted priority review by FDA
01 Apr 2009 GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
25 Mar 2009 Regeneron Announces Initiation of Phase 3 Gout Program with ARCALYST(R) (rilonacept)
25 Mar 2009 Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
25 Mar 2009 Alnara Pharmaceuticals Licenses Worldwide Rights to Liprotamase from Cystic Fibrosis Foundation
24 Mar 2009 Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization
24 Mar 2009 AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies
24 Mar 2009 Biovitrum gets access to Affibody® Technology
23 Mar 2009 Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
23 Mar 2009 Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
23 Mar 2009 Xencor Licenses Xtend Antibody Half-Life Prolongation Platform to Merck & Co., Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top